DGAP-News: Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec AG and 4-Antibody AG form strategic collaboration to innovate
antibody selection
09.05.2012 / 07:27
---------------------------------------------------------------------
* EVOTEC AND 4-ANTIBODY LAUNCH NEW HIGH CONTENT SCREENING PLATFORM FOR EARLY
ANTIBODY FUNCTIONALITY TESTING
* NOVEL SCREENING PROCESS INTEGRATES 4-ANTIBODY DISCOVERY PLATFORM AND
OFFERS EVOTEC CUSTOMERS NEW POSSIBILITIES FOR REDUCED LATE STAGE ATTRITION
AND BETTER EFFICACY
Hamburg, Germany; Basel, Switzerland - 09 May 2012: Evotec AG (Frankfurt
Stock Exchange: EVT, TecDAX) and 4-Antibody AG today announced the signing
of a strategic collaboration agreement under which Evotec will offer a fully
integrated antibody discovery and development service.
Evotec's novel and unique high throughput and high content screening
approach coupled with 4-Antibody's high throughput antibody selection
approach will now allow screening of large and diverse antibody populations
for desired functionality and activity at a much earlier stage of selection.
This unique combined approach is expected to substantially reduce attrition
rates at later development stages and is also expected to be particularly
beneficial in aiding earlier distinction and selection between antagonist
and agonist antibodies.
Evotec's fully integrated drug discovery and development infrastructure has
been adapted to facilitate screening of human antibody populations in
combination with high throughput/high content screening coupled to specific
biological assays. The new collaboration integrates the output from
4-Antibody's proprietary high throughput in vitro Retrocyte Display(R)
technology for rapid discovery of fully human antibodies into Evotec's high
throughput cell-based assay platform.
The Retrocyte Display(R) technology (Retroviral B lymphocyte Display) is a
high throughput cellular antibody expression platform which allows
expression and screening of full-length immunoglobulin antibody libraries in
mammalian B-lineage cells for the identification of antigen-specific fully
human monoclonal antibodies. B-lineage cells are designed by nature for
optimal antibody display, and are capable of generating
'better-behaved',fully human antibodies.
Dr Robert Burns, 4-Antibody's CEO, said: 'We're delighted to announce this
collaboration with Evotec. This will allow pharma players who elect to
fully out-source antibody drug discovery access to our platform. It's an
ideal partnership since it gives 4-Antibody access to a broader market
beyond our primary targets - the companies we think of as 'technology
internalizers'. Our primary business model remains unchanged but with the
Evotec collaboration we can now offer a fully integrated discovery to
development model in the antibody drug space for pharma players who are
looking for complete out-sourcing. Everyone in the drug discovery space
understands the desirability of introducing functional testing as early as
possible in the selection of drug candidates but I don't see other service
providers who can offer this fully integrated high throughput capability in
the antibody drug space.'
Dr Werner Lanthaler, CEO at Evotec added: 'We are excited to launch our
high-content screening capabilities for antibody selection in conjunction
with 4-Antibody, one of the technological leaders in the antibody field.
Through a combination of our capabilities, we target an approach to select
for functional antibodies. This 'EVOmAb' turn-key solution will deliver to
our customers a much higher chance to bring an antibody to the market than
traditional affinity-selected antibody approaches'
Both parties agreed to share financial rewards of this approach. Evotec
will initially pay a EUR 2m access fee to 4-Antibody, which will be fully
reimbursed from future returns. Going forward the Parties will share
profits.
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler(at)evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press
release contains forward-looking statements, which involve a number of risks
and uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statementsto reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.
End of Corporate News
---------------------------------------------------------------------
09.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
168796 09.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.05.2012 - 01:27 Uhr
Sprache: Deutsch
News-ID 1112151
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 84 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection
"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
